SCHEMBL823223

SCHEMBL823223

Cc1cccc(CCNC(=O)c2ccc3c4ccc(C(=O)O)c5c(C(=O)NCCc6cccc(C)c6)ccc(c6ccc(C(=O)O)c2c63)c54)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.54
RAB9A P51151 7/20 0.54
POLB P06746 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
TP53 P04637 2/20 0.47
MYC P01106 1/20 0.47
THRB P10828 2/20 0.47
ALDH1A1 P00352 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
CNR1 P21554 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5576816 1.00 NPC1 (0.54) NPC1RAB9APOLBSMN1; SMN2TP53
SCHEMBL823199 0.95 NPC1 (0.59) NPC1RAB9APOLBSMN1; SMN2TP53
SCHEMBL2212466 0.95 NPC1 (0.59) NPC1RAB9APOLBSMN1; SMN2TP53
SCHEMBL16352054 0.95 NPC1 (0.59) NPC1RAB9APOLBSMN1; SMN2TP53
SCHEMBL12038229 0.92 NPC1 (0.46) NPC1RAB9APOLBSMN1; SMN2TP53
SCHEMBL5574893 0.88 KDM4E (0.57) RAB9APOLBALDH1A1MEN1KMT2A
SCHEMBL16351275 0.86 NPC1 (0.50) NPC1RAB9APOLBSMN1; SMN2TP53
SCHEMBL12175719 0.86 NPC1 (0.50) NPC1RAB9APOLBSMN1; SMN2TP53
SCHEMBL16351304 0.86 NPC1 (0.50) NPC1RAB9APOLBSMN1; SMN2TP53
SCHEMBL12037459 0.86 NPC1 (0.50) NPC1RAB9APOLBSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530270-B2 Methods of preparing semiconductive compositions and devices EASTMAN KODAK COMPANY (US) 2013-09-10 US disclosed
US-8431433-B2 Methods of providing semiconductor layers from amic acid salts EASTMAN KODAK COMPANY (US) 2013-04-30 US disclosed
US-8411489-B2 Semiconducting devices and methods of preparing EASTMAN KODAK COMPANY (US) 2013-04-02 US disclosed
US-20110266523-A1 SEMICONDUCTING DEVICES AND METHODS OF PREPARING BANK OF AMERICA, N.A., AS AGENT 2011-11-03 US disclosed
US-20110269265-A1 METHODS OF PREPARING SEMICONDUCTIVE COMPOSITIONS AND DEVICES KODAK REALTY INC. 2011-11-03 US disclosed
US-20110269966-A1 SEMICONDUCTING ARTICLES CITICORP NORTH AMERICA, INC., AS AGENT 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269966-A1 SEMICONDUCTING ARTICLES ALAD, PORCN, DDC NPC1 2148/4885RAB9A 2482/4885POLB 3933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.